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A r t i c l e s
The walls of larger vessels and capillary beds are composed of vascular SMCs and pericytes, respectively 1 . Lineage tracking studies have shown that vascular SMCs in different vessels have distinct embryological origins 2 . For example, the basal aortic root is derived from the secondary heart field 3 , whereas the ascending aorta and the arch are neural crest derived 4 . Descending aortic SMCs originate from paraxial (somitic) mesoderm 5 . Coronary SMCs arise from the pro-epicardial organ, which is of lateral plate mesodermal origin 6 . Although information on the embryological origins of pericytes is relatively lacking, there is considerable phenotypic overlap between these cells and SMCs. Consistent with the phenotypic similarities, it appears that SMCs and pericytes in the same vascular region share common origins [7] [8] [9] [10] .
The diversity of SMC origins may in part contribute to the sitespecific localization of vascular diseases, including regional susceptibility to atherosclerosis 11, 12 , vascular calcification 13 and aortic aneurysm distribution 14 . Notably, aortic dissections occur preferentially at the interfaces where SMCs of distinct embryological origins meet. Together, these findings suggest that intrinsic lineage-derived differences between SMCs may play a role in the spatiotemporal pattern of vascular diseases. Therefore, a model system to investigate how SMC embryological origins influence development of vascular diseases would be valuable.
Currently, SMC derivation from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (iPSCs), collectively known as hPSCs, usually requires serum and does not encompass the concept of using a lineage-specific approach 15 . We report a chemically defined method for generating origin-specific SMCs from hPSCs through three intermediate lineages-neuroectoderm, lateral plate mesoderm and paraxial mesoderm. We used our in vitro system to predict the responses of different SMC subtypes to interleukin-1β (IL-1β), an inflammatory mediator, and validated the results using rat aortic SMCs of distinct origins. Our finding reveals that originspecific SMCs exhibit differential activation of matrix metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase 1 (TIMP1). Hence, our SMC subtypes could potentially be used to study origindependent disease susceptibility and also serve as a source of therapeutic cells for vascular regenerative medicine.
RESULTS

Mesoderm subtypes specified by modifying BMP and PI3K
The H9 hESC line, which is chromosomally normal ( Supplementary  Fig. 1a) , was used to study the specification of the various lineages from which SMCs arise. For neuroectoderm differentiation, we adopted our previously published protocol 16 , using fibroblast growth factor 2 (FGF2, 12 ng/ml) and the activin/nodal inhibitor SB431542 (10 µM). During the induction of neuroectoderm in hESCs, we observed a marked decrease in expression of the pluripotency marker NANOG within 2 d (Supplementary Fig. 1b) . The expression of neuroectoderm markers (GBX2, OLIG3 and SOX1) increased over time and peaked between day 6 and day 8, as documented before 16 . Extensive immunostaining for neuroectoderm markers (PAX6 and NESTIN) was observed in both hESCs and human iPSCs after Heterogeneity of embryological origins is a hallmark of vascular smooth muscle cells (SMCs) and may influence the development of vascular disease. Differentiation of human pluripotent stem cells (hPSCs) into developmental origin-specific SMC subtypes remains elusive. Here we describe a chemically defined protocol in which hPSCs were initially induced to form neuroectoderm, lateral plate mesoderm or paraxial mesoderm. These intermediate populations were further differentiated toward SMCs (>80% MYH11 + and ACTA2 + ), which displayed contractile ability in response to vasoconstrictors and invested perivascular regions in vivo. Derived SMC subtypes recapitulated the unique proliferative and secretory responses to cytokines previously documented in studies using aortic SMCs of distinct origins. Notably, this system predicted increased extracellular matrix degradation by SMCs derived from lateral plate mesoderm, which was confirmed using rat aortic SMCs from corresponding origins. This differentiation approach will have broad applications in modeling origin-dependent disease susceptibility and in developing bioengineered vascular grafts for regenerative medicine.
A r t i c l e s induction was observed, with >90% of the cells positive for both PAX6 and NESTIN (Supplementary Fig. 1c ). For mesoderm subtype differentiation, we used our previously described 36-h early mesoderm differentiation protocol 17 . A combination of FGF2 (20 ng/ml), phosphoinositide 3-kinase (PI3K) inhibitor (LY294002, 10 µM) and bone morphogenetic protein 4 (BMP4, 10 ng/ml), herein referred to as FLyB, was used (Fig. 1a, i (ii) BMP concentration gradient exists along the primitive streak (PS). On the basis of fate map studies, mesoderm subtypes emerge along the gradient on the embryo cylinder. (b) KDR and MEOX1 expression levels of hESCs differentiated for 36 h in FLyB, followed by 3.5 d in FGF2+LY294002 with Noggin (Nog), BMP4 (B) and/or activin (A) were determined by qRT-PCR. BMP4 concentrations ranged from 0 ng/ml (B0) to 100 ng/ml (B100). Data represent means ± s.e.m. (n = 3). Significant differences compared to day 0 population are indicated in black, whereas that between two groups are indicated in red (*, P < 0.05; **, P < 0.01). 
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During embryogenesis, specification of lateral plate mesoderm and paraxial mesoderm follows a posterior-anterior BMP gradient along the primitive streak 18 (Fig. 1a, ii) . We hypothesized that by varying the BMP4 concentration according to these developmental principles, we would obtain the relevant mesoderm subtypes from hPSCs. Studies have suggested that BMP signaling is a key driver of mesoderm [19] [20] [21] [22] , and BMP4 also cooperates with activin A to induce differentiation of mesendoderm, the precursor of mesoderm and endoderm 16 . We examined the roles of BMP4 and activin A in mesoderm subtype specification from the early mesoderm stage with constant concentrations of FGF2 (20 ng/ml) and LY294002 (10 µM). In the presence of activin A (10 ng/ml), BMP4 promoted the expression of the lateral plate marker KDR in a dose-dependent way (from 0 ng/ml to 100 ng/ml, that is, B0 to B100, respectively) (Fig. 1b) . Endogenous BMP signaling (B0 condition) was insufficient to promote KDR expression since Noggin, a BMP antagonist, produced the same effect as B0. The absence of activin A did not affect the development of lateral plate mesoderm as KDR was expressed as long as BMP4 was added. In contrast, absence of activin A promoted the expression of the paraxial marker MEOX1 in the absence of BMP (Noggin and B0 conditions). Activin A was therefore dispensable for mesoderm formation, whereas a high concentration of BMP4 enhanced lateral plate mesoderm specification but inhibited paraxial mesoderm specification.
We then evaluated the effect of 10 µM LY294002 (Ly) on mesoderm subtype specification. LY294002 has been shown to facilitate differentiation of hESCs 23 . Notably, we found that, in the presence of 20 ng/ml FGF2 (F) alone, Ly significantly promoted the expression of a panel of paraxial markers, MEOX1 (P = 0.0051), TBX6 (P = 0.0027), TCF15 (P = 0.0001) and PAX1 (P = 0.0087), versus no LY294002 (Fig. 1c) . Again, the presence of 50 ng/ml BMP4 (B50) inhibited the expression of all paraxial markers and promoted the expression of lateral plate markers. On the other hand, Ly significantly downregulated the lateral plate markers, LMO2 (P = 0.00024 in F, P = 0.00002 in FB50); PECAM1 (P = 0.0037 in F, P = 0.00167 in FB50); NKX2-5 (P = 0.0170 in F); and ISL1 (P = 0.0132 in F) compared to the no LY294002 condition. Hence, we established the optimal conditions for lateral plate and paraxial mesoderm subspecification to be FB50 and FLy, respectively.
We next determined the timescale of mesoderm subtype differentiation. NANOG expression decreased markedly within 2 d of differentiation of hESCs (Fig. 1d) . Brachyury (T), a primitive streak and early mesoderm marker, emerged transiently and peaked at 36 h after FLyB treatment. Further specification demonstrated that FB50 increased the expression of lateral plate genes (MESP1, KDR, NKX2-5 and ISL1) from as early as day 2 of differentiation, peaking at days 4 to 5. In contrast, FLy (blue lines) upregulated paraxial genes (TBX6, MEOX1, TCF15 and PAX1) only, with peak expression between days 3 and 5. Flow cytometry confirmed that FB50 treatment significantly promoted lateral plate mesoderm development, with 82.4 ± 5.1% KDR-expressing cells at day 5 compared to 2.12 ± 0.21% under the FLy treatment (P = 0.0004) (Supplementary Fig. 1d ). Meanwhile, FLy treatment resulted in 67.5 ± 7.3% TCF15-expressing cells at day 5, versus 1.25 ± 0.05% using FB50 (P = 0.0008), indicative of paraxial mesoderm formation primarily. Representative flow cytometric plots are shown in Figure 1e . Day 5 populations generated by either FB50 or FLy treatment also stained positively for their respective mesoderm subtype markers by immunofluorescence (Fig. 1f) . We therefore identified day 5 as the time point when the relevant mesoderm subtypes were optimally specified ( Fig. 1d-f and Supplementary Fig. 1c ). In summary, we devised a method to derive either paraxial or lateral plate mesoderm subtypes from hESCs.
Vascular SMCs generated efficiently from three lineages During vessel development, platelet-derived growth factor BB (PDGF-BB) induces differentiation of mesenchymal progenitors into vascular SMCs 24 . Upon investment of SMCs to the newly formed blood vessels, transforming growth factor-beta 1 (TGF-β1) promotes SMC maturation and regulates vessel remodeling 24 . We tested the effects of PDGF-BB and TGF-β1, as well as two other SMC inducers, retinoic acid (1 µM) and sphingosylphosphorylcholine (5 µM), on our derived intermediate populations, namely neuroectoderm, lateral plate mesoderm and paraxial mesoderm. Treatment with a combination of the two best inducers, PDGF-BB (10 ng/ml) and TGF-β1 (2 ng/ml) (PT treatment), promoted the highest expression of the SMC marker MYH11 from all the intermediate populations ( Supplementary Fig. 2a) . Combined protocols to derive origin-specific SMCs from hPSCs are outlined in Figure 2a .
The expression of multiple SMC markers increased over time with PT treatment and peaked between days 9 and 12, with upregulation of early SMC markers (ACTA2, TAGLN and CNN1) preceding the late markers (SMTN and MYH11) ( Fig. 2d ). Notably, there was little or no co-expression of CSPG4 and MYH11, suggesting that differentiating cells could adopt either an SMC or a pericyte-like phenotype. By day 12 of PT treatment, the pericyte-like population diminished, suggesting that the differentiation conditions had selected for SMCs (>86% MYH11 + ). Two isoforms of smoothelin, namely, smoothelin-A and smoothelin-B, have been reported to be specifically expressed in the visceral and vascular SMCs respectively 25 . Our derived SMCs exhibited up to tenfold lower smoothelin-A expression levels than did the human gut-derived sample, although smoothelin-B expression was similar to that seen in human aortic SMCs, suggesting that the differentiation conditions favored vascular SMC specification (Supplementary Fig. 2e ). This highly efficient process to derive origin-specific SMCs was reproducible in two hESC lines (H1 and H9) and a wild-type iPSC line (Fig. 2c) .
Because vascular SMCs arise more precisely from the neural crest, a descendant of neuroectoderm, we investigated whether there was transient formation of neural crest during neuroectoderm to SMC differentiation. Indeed, expression of BMP4 and BMP7, required for neural crest differentiation 26 , increased after PT treatment, before the peak expression of neural crest markers SNAI1 and SNAI2 at day 3 ( Supplementary Fig. 2f ). The other neural crest markers PAX3 and SOX10 displayed higher expression during the first 2 d of PT treatment as BMP expression levels increased. We reasoned that the spontaneous formation of neural crest could be due to the endogenous production of BMP4 and BMP7.
Microarray analysis was carried out to characterize the hPSCderived SMCs. Differentiated SMCs demonstrated downregulation of pluripotency genes, accompanied by upregulation of vascular SMC genes (Fig. 2d) . Furthermore, genes relating to neuronal, cardiac/endothelial/hematopoietic and skeletal muscle lineages, which are the other potential derivatives of neuroectoderm, lateral plate mesoderm and paraxial mesoderm, respectively, were repressed. POU5F1  ACTA2  TAGLN  TAGLN2  SMTN  CALD1  VIM  CNN1  MYH11  DES  MYLK  VCL  RGS5  AXL  PDGFRB  CSRP2  AEBP1  MAP2  GFAP  SLC6A1  TNNI3  TNNT2  MYH6  PTPRC  VWF  CDH5  MYOD1  TNNT3  TNNI1 Expression Low High 
Immunocytochemistry showed extensive staining for SMC markers in the derived SMCs and in the positive control, human aortic SMCs, but not in the negative control, human umbilical vein endothelial cells (HUVECs) (Fig. 2e) . Western blot also demonstrated the presence of mature SMC proteins, MYH11 and SMTN, in our derived SMCs and human aortic SMCs, which were absent in HUVECs (Fig. 2f) . Overall, these results suggest that by mimicking embryonic development, we developed a robust process to directly differentiate hPSCs into origin-specific SMCs using a series of growth factor manipulations in a chemically defined medium.
Origin-specific vascular SMCs are functional Despite the divergent initial differentiation routes, microarray analysis revealed that the three types of derived SMCs shared many genes (3,604) differentially upregulated compared to hESCs (falsediscovery rate, 0.1%) (Fig. 3a) . Among the highly enriched functional classifications of the 3,604 genes, there were the classical SMC functionality categories, such as blood vessel morphogenesis, extracellular matrix (ECM) interaction and actin cytoskeleton organization ( Fig. 3a; gene lists comprising the highlighted groups in yellow found in Supplementary Table 1) . Alternatively, the significantly enriched functional classifications of the nonoverlapping gene subsets revealed inherent differences among SMC subtypes (Supplementary Fig. 3a ). For example in neuroectoderm (NE)-SMC, there were categories related to myelination and synaptic transmission, both of which are neuronal characteristics, supporting the common neuroectoderm origin of NE-SMC and neurons. In particular, lateral plate mesoderm (LM)-SMC was highly enriched in genes promoting cell migration and consistent with this enrichment, these cells also displayed the greatest migration in a scratch assay (Supplementary Fig. 3b ).
To assess SMC contractile potential, we initially performed immunostaining for vinculin and phalloidin staining for actin filaments. Well-developed focal adhesion complexes were detected in all three SMC subtypes (Supplementary Fig. 3c) . The cells were then preloaded with a calcium-sensitive dye, Fluo-4. Carbachol (100 µM) stimulated an increase in Fluo-4 fluorescence intensity in the derived SMCs within 1 min of treatment (Fig. 3b, i) , indicating increased intracellular calcium flux. After 2 min of treatment, Fluo-4 intensity decreased, approaching original basal levels by 5 min. The same trend was observed in the positive control, human aortic SMCs but not in the negative control HeLa cells. Freshly dissociated rat aortic SMCs served as the optimal physiological control and demonstrated prolonged increase in intracellular calcium over the first 3 min. The derived SMCs exhibited similar peak fluorescence responses to both the cultured and freshly dissociated SMC controls (Fig. 3b, ii) . Timelapse microscopy showed that our SMCs and human aortic SMCs contracted in a tonic fashion during the 10 min of carbachol treatment ( Fig. 3c and Supplementary Videos 1-5) , consistent with the sustained contraction usually manifested by vascular SMCs in controlling vessel tone. Contracting cells exhibited a 10-20% change of cell surface area (n = 20). Over 50% and 20% of all derived SMCs contracted upon carbachol and angiotensin II treatments, respectively ( Supplementary Fig. 4a,b) . Paraxial mesoderm (PM)-SMC demonstrated a significantly higher percentage of contractile cells than other SMC subtypes (P = 0.036 versus NE-SMC in carbachol; P = 0.027 versus NE-SMC and P = 0.013 versus LM-SMC in angiotensin II).
To determine whether the hPSC-derived SMCs could contribute to vessel formation in vivo, we implanted Matrigel plugs with our SMCs and HUVECs (ratio 1:2) subcutaneously into immunodeficient mice for 2 weeks. Sections were immunostained using human-specific SMTN and PECAM1 antibodies. Luminal structures composed of 
HUVECs (PECAM1 + ) were observed (Fig. 3d) . HPSC-derived SMCs (SMTN + ) were recruited to peri-endothelial regions, reminiscent of their biological niche. There was 30-45% SMC coverage around the endothelial vessel structures with LM-SMCs displaying lower coverage levels (31.5 ± 5.1%) than the other two groups (43.1 ± 2.6% NE-SMC and 48.9 ± 3.1% PM-SMC). These results confirmed that the in vitro-derived SMCs were functional.
Origin-specific MKL2 requirement and responses to cytokines
To determine whether our system reliably generated origin-specific SMCs from hPSCs, we validated our model against reported findings from developmental studies. MKL2 is a transcriptional co-activator for serum response factor that plays a role in early embryogenesis 27 . Previous in vivo studies revealed the unique requirement for Mkl2 during SMC differentiation from neural crest but not mesoderm 28, 29 .
We postulated that MKL2 was essential only for NE-SMC specification and not for LM-or PM-SMC specification. To test this hypothesis, we silenced MKL2 using short interfering RNA (siRNA) in our intermediate populations (Fig. 4a,b) . We then induced SMC differentiation and found that the MKL2 siRNA-treated cells showed a significant decrease in SMC gene expression in NE-SMCs (CNN1, P = 0.0006; MYH11, P = 0.015; SMTN, P = 0.0023) compared to scrambled siRNA control, whereas LM-SMCs and PM-SMCs were unaffected (Fig. 4c) . Likewise, MKL2 knockdown resulted in a significant decrease in the percentage of MYH11 + ACTA2 + NE-SMCs (55.0 ± 4.8% MKL2 siRNA versus 86.7 ± 2.1% scrambled control, P = 0.0076, Fig. 4d ), but no reduction in SMCs derived from mesoderm origins. To confirm that we had generated origin-specific SMC subtypes, we used cytokines known to induce unique responses in aortic SMCs of distinct origins. Angiotensin II (Ang II) promotes medial hyperplasia in the ascending aorta (neuroectoderm derivative) but not the descending aorta (mesoderm derivative) 30 . TGF-β1 also encourages greater cell proliferation in SMCs of neuroectoderm origin compared to those of mesodermal origin 31, 32 . Consistent with the previous studies, NE-SMC proliferated in response to Ang II (1 µM, red lines) and TGF-β1 (5 ng/ml, green lines) over 3 d, but LM-SMC and PM-SMC did not (Fig. 4e) . Serum (10%, blue lines), a potent mitogen, induced proliferation in all the SMC subtypes although to a much lesser extent in PM-SMC. Cell cycle analysis confirmed that Ang II, TGF-β1 or serum each increased the proportion of NE-SMCs in S and G2-M phases compared to vehicle control after 24 h (Fig. 4f) . LM-SMC and PM-SMC showed higher S and G2-M populations only upon serum treatment. 
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Only NE-SMCs proliferated in response to TGF-β1 (Fig. 4e,f) . TGF-β1 may have enhanced cell proliferation by autocrine production of TGF-β2 and PDGFA 31, 32 . We investigated whether TGF-β1 stimulated greater auto-induction of TGF-β2 and PDGFA in SMCs of a neuroectoderm origin. TGFB2 (P = 0.002) and PDGFA (P = 0.0015) expression was significantly upregulated only in NE-SMCs after 10 h of TGF-β1 (5 ng/ml) treatment compared with vehicle control (Fig. 4g) . Correspondingly, elevated TGFB2 and PDGFA protein levels were found in NE-SMC lysates after TGF-β1 treatment (Fig. 4h) . Taken together, the data on requirement for MKL2 and their unique proliferative and secretory responses validate the hypothesis that our different SMC subtypes are analogous to the distinct lineage-dependent SMC populations documented in vivo.
SMC subtypes predict origin-specific MMP and TIMP activity To investigate a link between SMC developmental origins and susceptibility to vascular diseases, we treated our SMC subtypes with IL-1β (10 ng/ml), an atherogenic cytokine 33 . Rat SMCs isolated from various aortic regions (Supplementary Fig. 5 ) were tested in parallel. A panel of MMP and TIMP markers, known to be implicated in human atherosclerosis and aneurysm formation 34 , was investigated. We discovered that, broadly, LM-SMCs, NE-SMCs and PM-SMCs modeled similar responses to IL-1β as the rat aortic SMCs (bottom panel) of corresponding origins-root, arch and thoracic descending (Fig. 5a) . In particular, MMP9 and TIMP1 expression levels were differentially activated in our SMC subtypes, as were rat SMCs of distinct origins. The induction of Mmp9 relative to control in the rat SMCs was ~100-fold greater than that in the hPSC-derived SMCs. This could be due to species-specific variations or different degrees of SMC maturity, either of which could reflect the differences in level of activation for certain genes. Western blot analysis confirmed that the hPSC-derived SMCs (top panel) could predict the differential levels of MMP9 and TIMP1 proteins in the rat aortic SMCs after exposure to the same stimulus (Fig. 5b) . The human SMC subtypes also predicted the differential elastin (left panel) and collagen (right panel) degradation demonstrated by the rat aortic SMCs (Fig. 5c) . In summary, these results suggest that adult SMCs display heterogenous matrix remodeling responses due, in part, to their different origins. Notably, our in vitro-derived SMC subtypes are able to effectively model and predict the properties of their in vivo counterparts and consequently may have relevance in predicting origin-dependent disease responses.
DISCUSSION
We have developed a chemically defined monolayer system to generate origin-specific vascular SMCs from hPSCs with high efficiency. The initial induction to the intermediate lineages-neuroectoderm, lateral plate mesoderm and paraxial mesoderm-is instrumental in defining our subsequent SMC subtypes. Using developmental insights into the BMP gradient along the primitive streak, we have established conditions for mesoderm specification. Directed differentiation toward the paraxial mesoderm has not been previously reported. Moreover, our unpatterned lateral plate mesoderm is nonspecified tissue, in contrast to the specific lateral plate mesoderm derivatives, such as blood or cardiac lineages 19, 20, 22 , generated by other published protocols that also use BMP4. The hPSC-derived SMCs possess contractile function and participate in blood vessel formation in vivo. Although the SMC subtypes appear phenotypically and functionally indistinguishable, we provide evidence that they represent truly origin-specific subtypes. More specifically, we show that they recapitulate differential requirements for SMC fate commitment and unique biological responses to cytokines consistent with previous in vivo and ex vivo studies [28] [29] [30] [31] [32] . Our in vitro-derived SMC subtypes could be used to predict differential ECM remodeling responses of regionally distinct rat aortic SMC populations to IL-1β. Currently, there are no published data that functionally distinguish between SMCs from the lateral plate mesoderm and paraxial mesoderm. Nevertheless, we find that our PM-SMCs are less prone to serum-stimulated proliferation and ECM degradation compared to LM-SMCs and NE-SMCs. Moreover, a greater proportion of PM-SMCs become contracting The origin-specific SMCs (top panels) replicated similar trends of elastin and collagen degradation as the rat aortic SMCs (bottom panels) in response to IL-1β. Data represent means ± s.e.m. (n = 3). Significant differences compared to the vehicle controls (*, P < 0.05; ** , P < 0.01; ***, P < 0.001).
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A r t i c l e s cells in response to vasoconstrictors, suggesting that PM-SMCs may be relatively resistant to phenotypic modulation and retain a more differentiated phenotype than other SMC subtypes. Gene subsets uniquely upregulated in each of the SMC subtypes ( Supplementary  Fig. 3a ) reveal previously unknown differences, which may guide further studies on the functional relevance of the PM-SMC population to vascular pathology.
The diverse embryological origins of vascular SMCs are well recognized 2 . However, it remains unclear whether the site-specific presentation of some acquired vascular diseases is attributable to SMCs' intrinsic developmental origins. We have shown that origin-specific SMCs exhibit differential MMP and TIMP activation in response to IL-1β. MMP activation is associated with SMC phenotypic modulation 35 , which precedes aneurysm formation in experimental models 36 . Degradation of the vessel wall connective tissues by MMPs is a major pathological remodeling process in an array of human vascular diseases 34 . We hypothesized that the differential proteolytic ability of the medial SMC subtypes could influence the weakening of the aortic wall to different extents. Consequently, regional discrepancies in vessel mechanical properties may lead to aortic dissection at the boundaries where SMCs switch origins (Fig. 6) . MMPs also induce SMC migration during atheroma formation in atherosclerosis 37 . The most deleterious atherosclerotic lesions occur frequently in the coronary and carotid arteries, which arise from the lateral plate mesoderm and neuroectoderm, respectively. Accordingly, our results demonstrate that LM-SMCs and NE-SMCs are more predisposed to MMP activation than are PM-SMCs. We propose that hard-wired embryonic programs contribute to disease susceptibility, although other factors such as hemodynamic forces and physical structure of the vessels also play important roles.
The described differentiation system broadly covers most of the origins of vascular SMCs. Further patterning of the intermediate lineages, for example, the lateral plate mesoderm into secondary heart field or pro-epicardial lineage, may mimic more closely the precise origins of SMCs in the aortic root and coronary artery, respectively. Our protocols could potentially be extended to encompass these intermediate subpopulations in future studies. Moreover, a small number of SMC populations may be derived from embryonic tissues other than neuroectoderm, lateral plate mesoderm and paraxial mesoderm. For example, renal SMCs are thought to originate from the metanephric mesenchyme, an intermediate mesoderm derivative that is not modeled here. Additionally, it is likely that the hPSC-derived SMCs represent a fetal phenotype, possibly due to lack of heterotypic cell-cell interactions and in vivo microenvironment cues. In spite of this, our in vitro SMC differentiation system defines conditions for generating SMCs from different embryological origins. Elucidating the molecular mechanisms underlying origin-dependent differences in SMC behavior may provide clues to understanding how SMC origins influence a variety of vascular disease patterns.
Furthermore, our ability to produce large amounts of SMC subtypes from hPSCs should be beneficial in far-reaching applications in vascular disease modeling and regenerative medicine. Genetic syndromes 38, 39 and hereditary influences [40] [41] [42] seem to be closely linked to SMC dysfunction in the thoracic aorta 43 . Congenital vascular diseases, such as cono-truncal defects 44 or CADASIL 45 , feature mutations that predominantly affect neural crest-derived SMCs. Disease modeling with the appropriate origin-specific SMCs generated from patientderived iPSCs is therefore vital for accurate assessment and therapeutic discovery. Patient-matched SMCs may also be used to construct bioengineered blood vessels for coronary and peripheral artery bypass or hemodialysis grafts. In tissue or whole-organ regeneration, optimal outcomes require adequate vascularization. Therefore, to maximize success in both disease modeling and regenerative medicine, it may be useful to focus on SMCs that are derived from the same embryonic lineage as in the affected tissue or organ.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. Accession codes. Raw and processed data are available from the ArrayExpress microarray data repository under accession numbers E-MTAB-781 (SMC) and E-MTAB-464 (hESC). 
AuThoR ConTRiBuTionS
C.C. and S.S. developed the concept of generating origin-specific SMCs and designed the experiments. A.S.B. and R.A.P. developed the mesoderm specification protocols. C.C. performed experiments, analyzed data, and wrote and prepared Figure 6 The different embryological origins of aortic SMCs may contribute to the site of aortic dissection. Aortic SMCs originate from three distinct developmental lineages. The aortic root is derived from secondary heart field, a lateral plate mesoderm derivative (blue solid arrow), whereas the ascending aorta and arch are neural crest derived (red solid arrow). The descending aortic SMCs originate from paraxial/somitic mesoderm (green solid arrow). In this study, our in vitro hPSC-derived SMC subtypes predicted the differential MMP and TIMP activation in aortic SMCs of corresponding origins (dashed arrows) in response to an inflammatory mediator, IL-1β. We propose that the origin-specific SMCs display differential proteolytic ability in disease settings, which may result in differential loss of the structural integrity in different regions along the aortic wall. Such a difference in mechanical properties may predispose the sites of aortic dissection to occur preferentially at the boundaries between different SMC lineages (indicated by black jagged bolts). 
